Authors

Yangming Yu1, *, Yinhao Ding2, Yan Ran1


Departments

1Department, of Comprehensive Dentistry, Ningbo Stomatology Hospital, Ningbo City, 315000, Zhejiang Province, China - 2Department, of Endodontics, Ningbo Stomatology Hospital, Ningbo City, 315000, Zhejiang Province, China

Abstract

Objective: To explore the clinical efficacy of triamcinolone acetonide combined with immunotherapy in the treatment of oral mucosal diseases and its effect on the incidence of adverse reactions. 

Methods: The medical records of 106 patients with oral mucosal diseases treated in our hospital (January 2019-January 2021) were retrospectively analyzed. According to the treatment methods, 53 patients who received triamcinolone acetonide were set as the reference group (RG), while 53 patients who received triamcinolone acetonide combined with immunotherapy were set as the observation group (OG). The clinical efficacy of the two groups was compared and analyzed. 

Results: No remarkable differences in the general data were observed between the two groups (P>0.05). Compared with RG, OG achieved obviously lower effective rate, higher cured rate and higher total effective rate (P<0.05), shorter pain duration and mucosal healing time (P<0.05), better hemorheology indexes (plasma viscosity, whole blood viscosity, hematocrit, fibrinogen and ESR, P<0.05), and lower immune function indexes (IgA, IgM and IgG, P<0.05). After treatment, the inflammatory factor levels in both groups decreased, with remarkably lower TNF-α, IL-6, IL-8 and CRP levels in OG (P<0.05). Symptoms such as gastrointestinal discomfort, fever, rash and muscle atrophy occurred in both groups during treatment, with a slightly higher incidence of adverse reactions in RG compared with OG (P<0.05). 

Conclusion: Triamcinolone acetonide combined with immunotherapy can effectively improve the immune function of patients with oral mucosal diseases, with better curative effect and little adverse reactions, which is worth applying and popularizing. 

Keywords

Oral mucosal diseases, immunotherapy, triamcinolone acetonide, clinical efficacy.

DOI:

10.19193/0393-6384_2021_6_552